Based in Calgary, Alberta, Providence Therapeutics is a Canadian mRNA company focused on personalized cancer vaccines. During the pandemic, Brad Sorenson and his team developed a COVID vaccine that went head to head against Pfizer in clinical trials and held its own, yet almost no one in Canada ever heard about it.

In this episode, host Jim Wilson speaks with founder and CEO Brad Sorenson about a journey that is as personal as it is professional. In 2013, Brad's 13-year-old son Adam was diagnosed with glioblastoma and given a year to live. Thirteen years later, Adam is still here, and Brad walks through the extraordinary series of events that shaped both his son's survival and the company he built.

It is also a candid conversation about the realities of drug development in Canada and Brad's passionate call for the country to give patients the right to fight for their lives through compassionate access.

Cerebro Therapeutics is a biotech company based in Quebec City developing disease-modifying treatments for neurodegenerative disorders, with a primary focus on Parkinson's.

Unlike current therapies that only manage symptoms, Cerebro is working to stop the disease from progressing altogether.

In this episode, Jim Wilson speaks with president and co-founder Martin Levesque about a company that spun directly out of his research lab at Laval University.

Martin explains the science behind their approach, which combines immunotherapy and gene therapy to deliver protective antibodies across the blood-brain barrier in a single injection, and how a striking result in a mouse model convinced him the work needed to reach patients.

Martin also reflects on the leap from academic researcher to startup founder, the support of the Michael J. Fox Foundation, and why he believes the first treatment to halt Parkinson's could be made in Canada.

Based in Fredericton, New Brunswick, ResearchNB is the province's research funding agency. Think of the federal tri-councils CIHR, NSERC, and SSHRC combined into one and operating at a provincial level.

In this episode, Jim Wilson speaks with CEO Candice Pollack about an organization that has moved well beyond the traditional role of a passive funder. Candice explains how ResearchNB now actively connects researchers with industry, government, and community to make sure good research does not simply end up as a paper on a shelf, but moves toward real impact whether through commercialization, policy change, or better patient care.

Candice also makes a heartfelt case for New Brunswick as one of Canada's most underrated places for research and innovation, and why she believes the province's small, nimble approach is a strength rather than a limitation.